Previous 10 | Next 10 |
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22,...
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
2023-11-15 05:22:28 ET Cellectis ( NASDAQ: CLLS ) shares gained 9% premarket on Wednesday after the French biotech firm entered a binding agreement regarding the previously announced additional equity investment of $140M by AstraZeneca ( NASDAQ: AZN ). Earlier th...
2023-11-15 05:06:44 ET Related stories: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript JD.com: Catch The Falling Knife Again? Better Think Twice (Rating Downgrade) Tiger Global ...
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023. Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such i...
2023-11-08 08:34:45 ET Lumos Pharma ( LUMO ) +36% Q3 earnings call release Target Hospitality ( TH ) +25% Q3 earnings call release Baiyu Holdings ( BYU ) +23% . Upwork ( UPWK ) +23% Q3 earnings call release EVgo ( E...
2023-11-07 14:22:10 ET Cellectis SA (CLLS) Q3 2023 Earnings Conference Call November 07, 2023, 08:00 ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frattini - Chief Medical Officer Bing Wang -...
2023-11-06 17:24:57 ET Cellectis ( NASDAQ: CLLS ): Q3 Non-GAAP EPS of -$0.58. Revenue of $1.88M (+14.6% Y/Y). Cash position of $72 million as of September 30, 2023. Cash runway into 2026. For further details see: Cellectis Non-GAAP EPS of -$0.58, revenue of $...
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...